MX2023010183A - Polipeptidos variantes de actinohivina y metodos relacionados. - Google Patents

Polipeptidos variantes de actinohivina y metodos relacionados.

Info

Publication number
MX2023010183A
MX2023010183A MX2023010183A MX2023010183A MX2023010183A MX 2023010183 A MX2023010183 A MX 2023010183A MX 2023010183 A MX2023010183 A MX 2023010183A MX 2023010183 A MX2023010183 A MX 2023010183A MX 2023010183 A MX2023010183 A MX 2023010183A
Authority
MX
Mexico
Prior art keywords
actinohivin
related methods
variant polypeptides
cancer cells
polypeptides
Prior art date
Application number
MX2023010183A
Other languages
English (en)
Spanish (es)
Inventor
Nobuyuki Matoba
Matthew Dent
Original Assignee
Univ Louisville Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisville Res Found Inc filed Critical Univ Louisville Res Found Inc
Publication of MX2023010183A publication Critical patent/MX2023010183A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023010183A 2021-03-04 2022-03-04 Polipeptidos variantes de actinohivina y metodos relacionados. MX2023010183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163156715P 2021-03-04 2021-03-04
PCT/US2022/070961 WO2022187851A1 (en) 2021-03-04 2022-03-04 Actinohivin variant polypeptides and related methods

Publications (1)

Publication Number Publication Date
MX2023010183A true MX2023010183A (es) 2023-11-22

Family

ID=83155364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010183A MX2023010183A (es) 2021-03-04 2022-03-04 Polipeptidos variantes de actinohivina y metodos relacionados.

Country Status (9)

Country Link
US (1) US20240123026A1 (https=)
EP (1) EP4301389A4 (https=)
JP (1) JP2024509385A (https=)
CN (1) CN117098545A (https=)
AU (1) AU2022229597A1 (https=)
CA (1) CA3210629A1 (https=)
IL (1) IL305259A (https=)
MX (1) MX2023010183A (https=)
WO (1) WO2022187851A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12145966B2 (en) 2017-02-10 2024-11-19 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and methods of treatment using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012071492A1 (en) * 2010-11-23 2012-05-31 Georgia Tech Research Corporation Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells
EP3194973A1 (en) * 2014-09-17 2017-07-26 Institut Curie Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor
US12145966B2 (en) * 2017-02-10 2024-11-19 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and methods of treatment using them

Also Published As

Publication number Publication date
EP4301389A1 (en) 2024-01-10
CN117098545A (zh) 2023-11-21
WO2022187851A9 (en) 2022-09-29
WO2022187851A1 (en) 2022-09-09
CA3210629A1 (en) 2022-09-09
EP4301389A4 (en) 2025-03-12
AU2022229597A1 (en) 2023-10-19
IL305259A (en) 2023-10-01
JP2024509385A (ja) 2024-03-01
US20240123026A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
CY1126855T1 (el) Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
CL2024001473A1 (es) Conjugados de fármacos y anticuerpos anti-ccr7
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
MX2022001940A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
MX2020009757A (es) Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades.
CL2023003965A1 (es) Inhibidores cdk2.
MX2019000216A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
MX2020013320A (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
MX2017002333A (es) Conjugados novedosos de glicano y uso de los mismos.
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
SA519410840B1 (ar) إثارة باستشعاع الطاقة الضوئية
MX2023010183A (es) Polipeptidos variantes de actinohivina y metodos relacionados.
TWD191630S (zh) Reaction tube
DOP2021000113A (es) Anticuerpos antiperiostina y usos de estos
CL2025000366A1 (es) Composiciones y metodos para el tratamiento de presicion del cancer
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
MX2022014254A (es) Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis.
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
CL2023002812A1 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
CU20190019A7 (es) Combinaciones que incluyen abx196 útiles en el tratamiento del cáncer